Global Age-related Macular Degeneration Market Expected to Grow at 7.6% CAGR During 2016 – 2022 by P&S Market Research

The global age-related macular degeneration market was valued at $5,335.7 million in 2015, and it is expected to grow at a CAGR of 7.6% during 2016 – 2022.

Among the various types, the wet AMD segment is expected to witness the faster growth compared to dry AMD segment, during the forecast period. The global age-related macular degeneration market is growing at a significant rate, due to increasing healthcare cost, and increasing prevalence lifestyle associated diseases, such as obesity and hypertension. In addition, the growing geriatric population, increasing prevalence of AMD and increasing pipeline drugs for AMD are also driving the growth of the global age-related macular degeneration market.

Explore Report with Detailed TOC at: www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market

Age-related macular degeneration (AMD) is an acquired retinal disorder indicated by fundus changes. It is one of the most common forms of visual impairment in the geriatric population. It is a deterioration or degeneration of macular, leading to vision loss among people aged 60 years and above. The macula is a small part of retina responsible for sharpness and central vision.

Request Report Sample: www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market/report-sample

Smoking, obesity, high blood pressure, high cholesterol, poor diet, ultra-violet radiation, hereditary, and light eye color are some of the risk factors associated with AMD. In early stages, macular degeneration may not have symptoms, although with the progress of the disease it may have symptoms such as deterioration in central vision or dark spot, and blurriness.

Explore Related Research: www.psmarketresearch.com/industry-report/healthcare

Factors such as stringent regulatory requirements and increase in off label use are inhibiting the growth of the global market. The increasing awareness of AMD is the key trend observed in the global age-related macular degeneration market.

Geographically, North America dominated the global market of age-related macular degeneration in 2015; whereas, the Asia-Pacific market is expected to witness the fastest growth, during the forecast period.

Some of the key companies operating in the global age-related macular degeneration market include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech Pharmaceuticals, Inc., GlaxoSmithKline plc, StemCells Inc and Alimera Sciences, Inc.

GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION
Type
• Wet AMD
• Dry AMD

By Drug
• Lucentis
• Eylea
• Avastin
• Visudyne
• Others

By Geography
• North America
o U.S.
o Rest of North America

• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Rest of Europe

• Asia-Pacific
o Japan
o China
o India
o Rest of Asia-Pacific

• Rest of the World (RoW)

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Deep
Assistant – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

347 5th Ave. #1402- 210
New York City
United States

This release was published on openPR.